Skip to main content
ISU Abxis Co., Ltd. logo

ISU Abxis Co., Ltd. — Investor Relations & Filings

Ticker · 086890 ISIN · KR7086890001 KO Manufacturing
Open in API
Filings indexed 281 across all filing types
Latest filing 2026-06-17 Capital/Financing Update
Country KR South Korea
Listing KO 086890

About ISU Abxis Co., Ltd.

https://www.abxis.com/eng/index.do

ISU Abxis is a biopharmaceutical company specializing in the research and development of innovative biomedicines, primarily engineered antibody-based immunotherapies. Founded in 2001, the company leverages genetic recombination technology to create novel treatments. Its pipeline is focused on addressing significant unmet medical needs in oncology and rare diseases. Key development programs include therapeutics for cancers like Head and Neck Squamous Cell Carcinoma (ISU104) and treatments for rare genetic disorders such as Fabry disease (Fabagal). The company is dedicated to developing advanced antibody-based therapeutics to improve the quality of life for patients with difficult-to-treat conditions.

Recent filings

Filing Released Lang Actions
[기재정정]단일판매ㆍ공급계약체결
Capital/Financing Update Classification · 95% confidence The document details a contract extension for a single sales and supply agreement including specific contract amount, dates, and counterparties. It is a regulatory announcement about a business contract update rather than financial results, management changes, meetings, or specific report filings. The text does not include financial statements or report content but rather contract terms and related information. The document length is 3558 characters, relatively short and specific to contract details. It also references prior related contract announcements, indicating it is a contract-related update. Thus, the document fits best under 'Capital/Financing Update' (CAP) as it concerns sales/supply contract terms impacting company revenue or capital arrangements, rather than any other report or general regulatory filing category.
2026-06-17 Korean
임원ㆍ주요주주특정증권등거래계획보고서
Director's Dealing Classification · 95% confidence The document is titled '임원ㆍ주요주주 특정증권등 거래계획보고서' which translates to 'Report on Plans for Transactions of Specific Securities by Directors and Major Shareholders'. It shows detailed information about a planned transaction of shares including the dates, types of securities, ownership before and after the transaction, and transaction intent ('증여로 인한 수증' meaning 'receipt by gift'). The document references compliance with regulatory bodies (Securities and Futures Commission, Korea Exchange). The content focuses on insider planned transactions of shares by an executive or related party rather than a financial report or announcement of results. This matches the description for 'Director's Dealing' filings which report executives' or directors' personal share transactions or planned transactions. The document length is 4556 characters, not a brief announcement of a report publication or an officer certification. Therefore, this classification is 'DIRS' with high confidence.
2026-06-16 Korean
임원ㆍ주요주주특정증권등거래계획보고서
Director's Dealing Classification · 100% confidence The document text is in Korean and it relates to the trading plan report for executives and major shareholders involving specific securities transactions. It details ownership, trading plans, and notifications relevant to insider trading or share ownership disclosures. It references the securities regulatory bodies specifically the Korea Exchange and Financial Supervisory Commission, and is about planned transactions involving shares by a company insider. There is no financial statement, audit, earnings data, or voting results presented here. This type of filing corresponds to insider director or executive transactions involving company shares or securities. According to the filing definitions, "Director's Dealing" (Code: DIRS) matches this report type as it relates to personal share transactions by company directors and executives, often called insider trades or related disclosures
2026-06-16 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 97% confidence The document is labeled as “분기보고서” (Quarterly Report) covering the 26th fiscal period from January 1 to March 31, 2026. It includes full financial statements (balance sheet, income statement, cash flows), detailed notes, management’s analysis (이사의 경영진단 및 분석의견), and auditor’s opinion. It is the actual interim/quarterly report rather than an announcement or summary. Therefore it fits the “Interim / Quarterly Report” category. Q1 2026
2026-05-15 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 95% confidence The document is titled as a preliminary or provisional business performance announcement (영업(잠정)실적(공정공시)) for the period 2026-01-01 to 2026-03-31, which corresponds to a quarterly period. It contains summarized financial data such as sales, operating profit, and net income, but it is explicitly stated as provisional and unaudited. The document is relatively short (2265 characters) and serves as an announcement of preliminary financial results rather than a full interim or quarterly report with detailed financial statements and analysis. Therefore, it fits best as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. Q1 2026
2026-05-07 Korean
소속부변경
Regulatory Filings Classification · 95% confidence The document is a brief announcement about a change in the company's department affiliation (소속부변경) from 우량기업부 to 중견기업부, effective 2026-05-04. It does not contain financial data, report content, or detailed management information. It is a regulatory announcement about organizational change, which fits best under Regulatory Filings (RNS) as it does not match any other specific category.
2026-04-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.